BioNTech SE (BNTX) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	-$1.92	-$1.95	-1.6%	—	—	—
Q1 26	-$0.25	-$0.33	-32.0%	—	—	—
Q4 25	$0.1	-$0.12	-220.0%	—	—	—
Q3 25	-$1.41	-$1.6	-13.5%	—	—	—
Q2 25	-$2.35	-$1.73	+26.4%	—	—	—
Q1 25	$0.37	$1.08	+191.9%	—	—	—
Q4 24	-$1.61	$0.81	+150.3%	—	—	—
Q3 24	-$2.04	-$3.36	-64.7%	—	—	—
Q2 24	-$1.35	-$1.31	+3.0%	—	—	—
Q1 24	$2.45	$1.9	-22.4%	—	—	—
Q4 23	-$0.67	$0.67	+200.0%	—	—	—
Q3 23	-$0.73	-$0.79	-8.2%	—	—	—
Q2 23	$0.52	$2.05	+294.2%	—	—	—
Q1 23	$7.77	$9.26	+19.2%	—	—	—
Q4 22	$3.42	$6.98	+104.1%	—	—	—
Q3 22	$7.08	$6.45	-8.9%	—	—	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	-$4.7	—	—	$2.9B	—
FY24	—	-$2.77	—	—	$2.8B	—
FY23	—	$3.87	—	—	$3.8B	—
FY22	—	$38.8	—	—	$17.3B	—

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$61.6M	$127.6M	$108.6M	$482.3M	$19B	$17.3B	$3.8B	$2.8B	$2.9B
YoY change	—	+107.1%	-14.9%	+344.1%	+3.8K%	-8.78%	-77.9%	-28%	+4.32%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	61.6M	127.6M	108.6M	482.3M	19B	17.3B	3.8B	2.8B	2.9B
Cost of revenue	9.3M	13.7M	17.4M	59.3M	2.9B	3B	599.8M	541.3M	641.8M
Gross profit	52.3M	113.9M	91.2M	423M	16.1B	14.3B	3.2B	2.2B	2.2B
Gross margin	84.9%	89.3%	84%	87.7%	84.7%	82.7%	84.3%	80.3%	77.6%
Research & development	85.5M	143.1M	226.5M	645M	949.2M	1.5B	1.8B	2.3B	2.1B
Selling, general & administrative	29.5M	27.1M	43.3M	108.5M	327.2M	541.2M	557.7M	599M	698.2M
Operating expenses	112.9M	165.5M	267.8M	505.4M	1.1B	2B	2.3B	2.8B	2.9B
Operating income	-61.3M	-53.9M	-181.5M	-82.4M	14.9B	12.3B	904.2M	-595.7M	-640.7M
Operating margin	-99.5%	-42.3%	-167.1%	-17.1%	78.7%	71.1%	23.7%	-21.7%	-22.3%
Non-operating income, net	-26M	6M	2.3M	-59.9M	145.1M	620.7M	-67.8M	-69.4M	-397.5M
Pretax income	-85.9M	-47.7M	-179.4M	-145.8M	15B	13B	1.2B	-677.7M	-1.1B
Income tax	45K	600K	-200K	-161M	4.8B	3.5B	255.8M	-12.4M	85.3M
Net income	-86M	-48.3M	-179.2M	15.2M	10.3B	9.4B	930.3M	-665.3M	-1.1B
Net margin	-139.5%	-37.8%	-165%	3.15%	54.2%	54.5%	24.4%	-24.2%	-39.6%
EBITDA	-48.7M	-30.1M	-146.1M	-45.2M	14.9B	11.8B	1.2B	-297.7M	-256.3M
EPS	-0.38	-0.21	-0.85	0.06	42.2	38.8	3.87	-2.77	-4.7
Diluted EPS	-0.38	-0.21	-0.85	0.06	39.6	37.8	3.83	-2.77	-4.7

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	895.3M	1.5B	187.6M	128.7M	1.4B	1.2B	182.8M	260.8M	1.5B	907.4M	118.1M	105.6M
Cost of revenue	161.8M	179.1M	59.1M	59.8M	207.8M	243.5M	83.8M	76.4M	148.3M	333.3M	71.4M	97M
Gross profit	733.5M	1.3B	128.5M	68.9M	1.2B	946.5M	99M	184.4M	1.4B	574.1M	46.7M	8.6M
Gross margin	81.9%	87.9%	68.5%	53.5%	85.6%	79.5%	54.2%	70.7%	90.2%	63.3%	39.5%	8.14%
Research & development	497.9M	577.8M	507.5M	584.6M	639.1M	611.8M	525.6M	509.1M	564.8M	505.4M	557M	551M
Selling, general & administrative	153.5M	149.4M	132.6M	183.8M	174.8M	132.1M	120.6M	137.4M	148.5M	291.7M	163.8M	197.8M
Operating expenses	660.4M	724.9M	635.7M	1B	1.2B	79.3M	633.1M	662.9M	716.7M	854.6M	717.9M	947.3M
Operating income	73.1M	598M	-507.2M	-966.2M	12.2M	867.2M	-534.1M	-478.5M	653.9M	-280.5M	-671.2M	-938.7M
Operating margin	8.16%	40.4%	-270.4%	-750.7%	0.84%	72.9%	-292.2%	-183.5%	43.1%	-30.9%	-568.3%	-888.9%
Non-operating income, net	55M	-51.8M	—	—	—	—	—	79.1M	-628.9M	58.2M	46.1M	17.3M
Pretax income	227.4M	663.2M	-331.8M	-805.8M	184.3M	301.2M	-445.4M	-402.7M	24.7M	-227.4M	-568.1M	-858.7M
Income tax	66.8M	205.3M	-16.7M	2M	-45.8M	41.7M	-29.6M	-16.1M	53.4M	77.6M	-36.2M	-37.9M
Net income	160.6M	457.9M	-315.1M	-807.8M	230.1M	259.5M	-415.8M	-386.6M	-28.7M	-305M	-531.9M	-820.8M
Net margin	17.9%	31%	-168%	-627.7%	15.9%	21.8%	-227.5%	-148.2%	-1.89%	-33.6%	-450.4%	-777.3%
EBITDA	270.7M	507.4M	-288.8M	-748.6M	245.2M	464.4M	-368.7M	-427.4M	1.4B	-569.8M	-488.9M	-606.4M
EPS	0.67	—	-1.31	-3.36	0.82	1.08	-1.73	-1.6	-0.12	-1.25	-2.1	-3.24
Diluted EPS	0.66	—	-1.31	-3.36	0.81	1.08	-1.73	-1.6	-0.12	-1.25	-2.1	-3.24

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	—	—	—	6.9B	—	60.7B	35.3B	23.4B	27.4B	23B	24.9B
Enterprise value	—	—	—	6.5B	—	58.9B	21.4B	7.1B	10.8B	8.4B	13.2B
Shares outstanding	—	218.9M	218.9M	204.1M	244.4M	235.5M	234.8M	222.1M	240.2M	241.7M	241.7M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	—	—	—	—	—	5.9	3.74	25.2	—	—	160.8
P/S	—	—	—	63.7	—	3.2	2.04	6.14	9.95	8.02	9.39
P/B	—	—	—	14	—	5.1	1.76	1.16	1.41	1.2	1.23
EV/EBITDA	—	—	—	-44.3	—	3.97	1.81	6.15	-36.4	-32.8	-8.4
EV/Sales	—	—	—	59.6	—	3.11	1.24	1.86	3.94	2.93	4.38
Earnings yield	—	—	—	—	—	17%	26.8%	3.97%	—	—	0.62%
FCF yield	—	—	—	-3.9%	—	1.21%	37.5%	19.9%	-0.89%	-1.27%	-1.14%
PEG	—	—	—	—	—	—	—	—	—	—	1.57

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	—	84.9%	89.3%	84%	87.7%	84.7%	82.7%	84.3%	80.3%	77.6%	8.14%
Operating margin	—	-99.5%	-42.3%	-167.1%	-17.1%	78.7%	71.1%	23.7%	-21.7%	-22.3%	-806.6%
Net margin	—	-139.5%	-37.8%	-165%	3.15%	54.2%	54.5%	24.4%	-24.2%	-39.6%	-63.6%
ROE	—	178.3%	-18.1%	-36.3%	1.11%	86.5%	47%	4.6%	-3.43%	-5.91%	-9.3%
ROA	—	-22.9%	-7.39%	-22.5%	0.66%	65%	40.5%	4.04%	-2.95%	-5.17%	-5.41%
ROIC	—	36%	59.5%	-387.2%	-31.2%	100.9%	144.5%	18.1%	-20.7%	-13.9%	-37.5%
Return on tangible assets	—	-41.4%	-10.1%	-29%	0.76%	66.7%	41.3%	4.5%	-3.3%	-6.3%	-10.1%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	—	1.2	3.56	4.05	2.75	4.33	7.43	9.43	7.45	7.54	7.85
Quick ratio	—	1.17	3.51	3.97	2.64	4.18	7.28	9.26	7.34	7.49	7.8
Debt / equity	—	-1.04	0.2	0.15	0.18	0.03	0.01	0.01	0.01	0.01	0.02
Debt / assets	—	0.13	0.08	0.09	0.1	0.02	0.01	0.01	0.01	0.01	0.02
Net debt / EBITDA	—	2.5	11.9	3.06	24.5	-0.12	-1.17	-14.1	55.5	57	56
Interest coverage	—	-126.1	-26.7	-104.5	-71.9	2.8K	759.5	—	-52.8	-73	-73
Effective tax rate	—	0%	0%	0%	0%	31.6%	27.2%	21.6%	0%	0%	0%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	—	0.28	0.58	0.53	1.97	80.6	73.7	17.2	11.5	11.9	10.7
EPS (basic)	—	-0.38	-0.21	-0.85	0.06	42.2	38.8	3.87	-2.77	-4.7	-4.7
EPS (diluted)	—	-0.38	-0.21	-0.85	0.06	39.6	37.8	3.83	-2.77	-4.7	-7.64
Book value per share	—	-0.22	1.22	2.42	5.61	50.5	85.4	91.2	80.8	79.5	80.4
FCF per share	—	-0.5	-0.58	-1.32	-0.4	3.12	56.3	21	-1.02	-1.21	1.76
Cash per share	—	0.79	1.88	2.55	5.51	8.81	59.9	74.5	69.9	61.5	53.6
Capex per share	—	0.09	0.13	0.19	0.27	0.53	1.4	1.13	1.19	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	—	31.1%	22.9%	35.5%	13.4%	0.65%	1.9%	6.55%	10.4%	—	—
Capex / operating cash flow	—	-24.3%	-49.2%	-19.4%	-120.7%	2.65%	1.89%	4.37%	118.5%	—	—
Payout ratio	—	—	—	—	0%	0%	5.13%	0%	0%	—	0%
Dividend yield	—	—	—	—	—	0%	1.37%	0%	0%	—	—

Yield

—

trailing twelve months

Frequency

—

Last dividend

$2.111

ex-dividend Jun 2, 2022

Payout ratio

of earnings

Dividend growth

0 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Jun 2, 2022	$2.111

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$895.3M	$1.5B	$187.6M	$128.7M	$1.4B	$1.2B	$182.8M	$260.8M	$1.5B	$907.4M	$118.1M	$105.6M
YoY change	-74.1%	-65.4%	-85.3%	-23.3%	+61.5%	-19.5%	-2.56%	+102.6%	+5.06%	-23.7%	-35.4%	-59.5%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	305.2M	172.4M	411.8M	520.8M	1.3B	2.1B	14.1B	16.5B	16.8B	14.9B
Receivables	3.2M	4.6M	18.9M	11.9M	165.5M	12.4B	7.1B	2.2B	1.5B	924.2M
Inventory	3.3M	3.9M	5.8M	11.7M	64.1M	502.5M	439.6M	357.7M	283.3M	110.7M
Total current assets	318.1M	189.6M	449M	560.2M	1.7B	15.1B	21.9B	19.5B	18.8B	16.1B
Property, plant & equipment	32.6M	49.8M	66.2M	93.1M	245.1M	345.5M	614.6M	761.8M	945.2M	1.1B
Goodwill & intangibles	22.4M	167.1M	176.1M	178.9M	327M	404.8M	439.4M	2.3B	2.3B	3.9B
Total assets	390M	374.7M	653M	797.6M	2.3B	15.8B	23.3B	23B	22.5B	22B
Accounts payable	6.2M	52.5M	41.7M	20.5M	102.3M	160M	204.1M	354M	426.7M	534.9M
Short-term debt	—	—	—	5.3M	9.1M	129.9M	36M	28.1M	39.5M	52.2M
Total current liabilities	56.6M	158.5M	126.1M	138.1M	606M	3.5B	3B	2.1B	2.5B	2.1B
Long-term debt	26.7M	50.3M	54.2M	68.9M	231M	171.6M	176.2M	191M	214.7M	215.2M
Total liabilities	358.1M	422.9M	386M	304.2M	946.8M	3.9B	3.2B	2.8B	3.1B	2.8B
Shareholders' equity	31.9M	-48.2M	267M	493.5M	1.4B	11.9B	20.1B	20.2B	19.4B	19.2B
Total debt	26.7M	50.3M	54.2M	74.2M	240.1M	301.5M	212.2M	219.1M	254.2M	267.4M
Net debt	-277M	-121.8M	-357.3M	-444.9M	-970.1M	-1.4B	-13.7B	-11.4B	-9.5B	-7.4B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	15.7B	16.5B	15.7B	17.3B	19.4B	16.8B	14.1B	14B	14.5B	14.9B	14.6B	14.8B
Receivables	2B	2.2B	1.6B	75.8M	1.1B	1.5B	956.5M	1.4B	690.8M	924.2M	539.2M	163.9M
Inventory	415.7M	357.7M	345.4M	340.1M	352M	283.3M	254.4M	230.7M	225.7M	110.7M	103.8M	100.6M
Total current assets	18.7B	19.5B	18.3B	18.3B	21.5B	18.8B	15.6B	15.9B	15.8B	16.1B	15.5B	15.3B
Property, plant & equipment	925.9M	761.8M	1B	1.1B	1.3B	945.2M	1.3B	1.2B	1.2B	1.1B	1.3B	1.2B
Goodwill & intangibles	2.1B	2.3B	2.4B	2.5B	2.9B	2.3B	3.8B	3.7B	3.5B	3.9B	3.8B	3.6B
Total assets	22.2B	23B	22.3B	22.2B	26B	22.5B	21.2B	21.6B	21.3B	22B	21.1B	20.3B
Accounts payable	222.7M	354M	298.8M	881.5M	885.7M	426.7M	443.8M	504.2M	399.8M	534.9M	468.8M	646.7M
Short-term debt	40M	28.1M	31.3M	35.3M	43.4M	39.5M	55.5M	52.4M	53.4M	52.2M	56.7M	57.2M
Total current liabilities	1.8B	2.1B	1.6B	2.4B	2.9B	2.5B	1.5B	1.9B	2.2B	2.1B	1.8B	1.9B
Long-term debt	161.9M	191M	205M	219.3M	239.6M	214.7M	237.5M	217.2M	192M	215.2M	246.1M	258.9M
Total liabilities	2.3B	2.8B	2.3B	3.2B	3.8B	3.1B	2.3B	3.1B	2.9B	2.8B	2.4B	2.6B
Shareholders' equity	19.9B	20.2B	20B	19.1B	22.2B	19.4B	18.9B	18.5B	18.5B	19.2B	18.7B	17.8B
Total debt	201.9M	219.1M	236.3M	254.6M	283M	254.2M	293M	269.6M	245.4M	267.4M	302.8M	316.1M
Net debt	-13.3B	-11.4B	-8.7B	-10.1B	-10.9B	-9.5B	-9.9B	-10B	-9.8B	-7.4B	-9.6B	-9.4B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	-85.9M	-47.7M	-179.4M	-145.8M	15B	13B	1.2B	-677.7M	-1.1B
Depreciation & amortization	10.5M	22M	33.9M	38.7M	75.2M	123.3M	183.4M	298M	382.8M
Stock-based compensation	5.9M	7.6M	30.2M	32.1M	93.9M	108.6M	51.4M	100.9M	106.2M
Change in working capital	-8M	-41.1M	-83.5M	-93.1M	-10.7B	4.5B	5.6B	1.2B	537.8M
Operating cash flow	-78.8M	-59.3M	-198.6M	-53.7M	4.7B	17.4B	5.7B	240.7M	456M
Capital expenditure	-19.1M	-29.2M	-38.6M	-64.8M	-124.1M	-328.6M	-250.1M	-285.3M	—
Investing cash flow	-19.1M	-29.2M	-44.7M	-125.4M	-539.6M	-1.2M	-6.5B	-1.9B	-1.7B
Dividends paid	—	—	—	0	0	-484.3M	0	0	—
Share repurchases	—	—	—	0	0	-986.4M	-738.5M	0	0
Financing cash flow	-1.6M	365.2M	383.3M	894.7M	94.2M	-1.4B	-778.6M	-45.9M	-52.9M
Net change in cash	-99.6M	276.7M	140M	715.6M	4.2B	16B	-1.6B	-1.7B	-1.3B
Free cash flow	-110.3M	-126M	-269.6M	-98.9M	735.7M	13.2B	4.7B	-244.6M	-293M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	—	—	—	—	—	—	—	—	24.7M	-227.4M	-568.1M	-858.7M
Depreciation & amortization	41.3M	78.8M	38.3M	57.8M	44.4M	165.4M	42.8M	51M	124.2M	164.8M	121.3M	266.1M
Stock-based compensation	—	—	—	—	—	—	—	—	27.9M	24.1M	22.8M	20.9M
Change in working capital	—	—	—	—	—	—	—	—	644M	-227.4M	66.2M	593.9M
Operating cash flow	41.3M	78.8M	38.3M	57.8M	44.4M	165.4M	42.8M	51M	780.7M	309.5M	-421M	10.5M
Capital expenditure	—	—	—	—	—	—	—	—	—	—	—	—
Investing cash flow	—	—	—	—	—	—	—	—	-889.6M	-2.7B	2.7B	-48.1M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	—	—	—	-129.2M
Financing cash flow	—	—	—	—	—	—	—	—	-11.5M	-19M	26.4M	-108.5M
Net change in cash	41.3M	78.8M	38.3M	57.8M	44.4M	165.4M	42.8M	51M	-120.4M	-2.4B	2.3B	-146.1M
Free cash flow	—	—	—	—	—	—	—	—	742.1M	247.4M	-499.9M	-44.9M

BioNTech SE Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement